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1. SUMMARY 
Nanotechnology has been advancing relentlessly and the use of nanoparticles has 
increased rapidly as they have been applied in numerous industrial and medical sectors. For 
instance, Silver nanoparticles can be found in aerosols, Zinc and Titanium oxides are important 
components of sunscreen and applications of different nanoparticles have proved to be relevant 
in biomedicine as multifunctional drug carriers or in novel cancer therapies. 
Nevertheless, potential dangers from nanoparticle exposure cannot be ignored.  
Nanoparticles may damage organisms. In vitro, studies have found certain nanoparticles to be 
able to break DNA helices, denaturalise vital proteins, disrupt gene expression or alter plasma 
coagulation. In vivo, they can induce inflammation and stimulate or suppress the immune 
system. Due to the ease of exposure to nanoparticles, the study and understanding of their 
potential toxicity is fundamental. The area of this research goes by the name of Nanotoxicology. 
Herein, different sized particles of ZnO, characterized by different methods, were used to 
study their interaction with plasma proteins, both human and rat. Plasma proteome alteration, as 
a result of the presence of ZnO in different conditions, has been evaluated in order to gain 
knowledge of potential toxicity from these nanoparticles and its consequences.  
Experimental results reported plasma coagulation delays, especially when studying the 
intrinsic coagulation pathway. Rat and human plasma were not equally affected by the ZnO 
particle’s presence; SDS-PAGE gels revealed significant differences among proteins adsorbed 
on the particles depending on the organism studied. The formation of a proteic coating on ZnO 
particles, the protein corona, was confirmed through observations on TEM and consequent 
stabilization of particle dispersion was reported by DLS. 
Keywords: ZnO nanoparticles, Nanotoxicity, Protein corona, Plasma coagulation, SDS-PAGE, 
TEM. 
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2. RESUM 
La nanotecnologia avança sense aturador i l’ús de nanopartícules ha augmentat ràpidament 
degut a la seva aplicació en nombrosos sectors industrials i mèdics. Per exemple, es poden 
trobar nanopartícules de plata en aerosols, òxids de zinc i de titani en cremes solars, i s’han 
realitzat rellevants avenços en el camp de la biomedicina gràcies a l’aplicació de diferents 
nanopartícules com a portadors multifuncionals de fàrmacs, o en noves teràpies contra el 
càncer, entre d’altres. 
No obstant, no es poden ignorar els potencials riscs de toxicitat davant l’exposició a 
aquestes nanopartícules, ja que poden danyar l’organisme. Estudis in vitro han observat com 
determinades nanopartícules són capaces de trencar l’hèlix d’ADN, desnaturalitzar proteïnes 
vitals, interrompre expressió genòmica o alterar la coagulació sanguínia. In vivo, aquestes 
poden causar inflamació o alterar el sistema immunitari. Degut a que les nanopartícules poden 
ser fàcilment trobades en productes disponibles al mercat, l’estudi i la comprensió del seu 
potencial tòxic és fonamental. L’àrea encarregada d’aquesta recerca s’anomena 
Nanotoxicologia.  
En aquest estudi, nanopartícules de diferents mides de ZnO, caracteritzades mitjançant 
diferents mètodes, han estat usades per a estudiar la seva interacció amb plasma humà i de 
rata. L’alteració proteica, com a resultat de la presència de ZnO en diferents condicions, han 
sigut avaluades per tal d’adquirir coneixements sobre la potencial toxicitat d’aquestes 
nanopartícules i les seves conseqüències.  
Els resultats experimentals obtinguts informen de retards en la coagulació del plasma, 
especialment en el camí intrínsec de la coagulació. Els plasmes de rata i home no es veien 
afectats de la mateixa manera en presència de les partícules de ZnO; els gels de SDS-PAGE 
revelaven diferències significatives entre les proteïnes adsorbides a les partícules depenent de 
l’organisme estudiat. La formació d’un embolcall proteic al voltant de les partícules de ZnO, la 
corona proteica, va ser confirmat mitjançant observacions en TEM, i la conseqüent 
estabilització de la dispersió de les partícules va ser observada mitjançant DLS. 
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Keywords: Nanoparticules ZnO, Nanotoxicitat, Corona proteica, Coagulació sanguínia, SDS-
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3. INTRODUCTION 
3.1 NANOTECHNOLOGY AND NANOPARTICLES 
Nanotechnology is defined, by the National Nanotechnology Initiative, as the manipulation of 
matter sized from 1 to 100 nanometers, known as Nanomaterials.  
Nanoparticles (NPs) have been found to be useful in a wide variety of scientific and 
industrial areas. For instance, Silver NPs can be found in aerosols, Zinc and Titanium oxides 
are important components of sunscreen [1] and numerous NPs have proved to be relevant in 
biomedicine as multifunctional drug carriers or in novel cancer therapies [2]. Specifically, ZnO 
NPs have been found to apply as bactericides or anticarcinogenics [3], [4]. 
Unlike regular sized particles, NPs have high surface/volume ratios that increase as the 
nanoparticle size decreases [5]. That results in high reactivity with prominent physical properties 
and advantageous characteristics that are being used in several fields of science and industry.  
Although it is encouraging for scientific research and innovation, NP’s numerous 
applications throughout commercially available products, therefore their easy exposure to 
humans, have aroused concern for their potential toxicity. In fact, potential dangers from 
nanoparticle exposure have been reported:  In vitro, certain nanoparticles are able to break 
DNA helices, denaturalise vital proteins, disrupt gene expression or alter plasma coagulation. In 
vivo, they can induce inflammation and stimulate or suppress the immune system [6]. A new 
science named Nanotoxicology was born to deal with this matter.  
Different effects derived from nanoparticles have proven to be based on their size, their 
shape and curvature, their surface area, or their surface charge [7]–[9]. All these items regulate 
the affinity between the particle and the proteins in the media, thus conforming a dense cloud 
surrounding the particles of critical importance, called the Protein Corona. 
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3.2 PROTEIN CORONA 
The biological activity of the nanoparticles is mainly based on the Protein Corona. When 
suspended, the nanoparticle interacts with the proteins in the media and binds them around 
itself. This process results in the total covering of the nanoparticle as shown in Figure 3.1. 
 
 
 
 
 
The protein corona becomes the interface between the particle and the cellular system. 
Therefore, the nanoparticle-corona complex is the entity that represents “what the cell sees”. It 
has been experimentally found that the biological activity originated by nanoparticles is based 
on the protein corona bound to them, and not on so much the bare characteristics of the particle 
itself [8]. 
As stated by the Vroman effect, we should expect the most mobile proteins to bind rapidly to 
the nanoparticle, and afterwards being replaced in equilibrium with other proteins of lower 
mobility and higher affinity to the particle [10]. Therefore, after a certain time of incubation, we 
could expect to divide the corona in two parts, the so called “Hard-corona”, an inner layer 
formed by the proteins with highest affinity to the particle, and the “Soft-corona”, formed of 
proteins of highest mobility and not so much affinity to the particles (Figure 3.2). 
 
 
 
 
 
 
 
Figure 3.1 Representation of the Protein Corona. To the left, 
the nanoparticle alone. To the right, the nanoparticle in 
blood suspension all covered by proteins. 
Figure 3.2 Representation of the hard-corona, 
inner layer, and soft- corona, outer layer. 
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The Vroman effect suggested that the biological activity could change through time. 
Nevertheless, this protein corona has been reported to be formed at <0.5 min. After that, 
although it was observed kinetic flowing of proteins in-and-out the corona, the corona did only 
change quantitatively and not qualitatively [8]. Thus, the biological activity remained the same, 
determined since the very first moment. That being said, the knowledge on the regulation of the 
protein corona is still limited.  
Before further explanation of causes and consequences found in studies regarding the 
protein corona, essential information regarding the physiological media herein studied will be 
exposed in the following section. 
3.3 PHYSIOLOGICAL MEDIA 
Herein, our particles will be incubated in plasma, which is significantly different from blood or 
serum [11]: 
1. Whole blood is a suspension of necessary nutrients, organic molecules, and 
cellular components (Erythrocytes, Leucocytes, Platelets…) immersed in aqueous 
media, plasma. 
2. Plasma approximately consists of 55% of the whole blood volume. It is the 
aqueous media where blood cellular elements are immersed, which can be 
separated from it through centrifugation or sedimentation. Plasma is formed 
basically for water (91%), proteins (7%) and other solutes such as nutrients, 
electrolytes, etc. 
3. Serum is collected after blood coagulation, centrifuged and separated from its 
cellular elements. Therefore, it is essentially plasma lacking blood coagulation 
factors and related proteins. 
 Possible consequences derived from NPs incubation will be studied through the evaluation 
of changes in plasma’s behavior, such as alterations in blood coagulation, thus leading to the 
identification of the proteins affected.  
3.3.1 Plasma Proteins 
Human plasma contains approximately 1,200 different proteins [12], although a vast majority 
of which are found in an almost insignificant concentration. Table 3.1 describes the 
characteristics and functions of some of the most abundant of these proteins. 
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Protein Characteristics Functions 
Albumin [13] 54% of plasma proteins 
MW=65kDa 
4.5g/100ml 
Transports poorly soluble molecules, binds 
toxic heavy metal ions, provides a reserve 
of protein and maintains plasma colloidal 
osmotic pressure. 
1-antitrypsin 
[13] 
MW=45kDa 
250mg/100ml 
Responsible for nearly all the protease 
inhibiting capacity of serum 
Fibrinogen [13] MW=340kDa 
300mg/100ml 
Precursor of fibrin, the insoluble protein of 
blood clots 
Protein C [14] MW=62kDa 
0.500mg/100ml 
Regulates anticoagulation 
Transferrin [13] MW=80kDa 
290mg/100ml 
Transports iron  
2-macroglobulin 
[15] 
MW=185kDa 
1.2mg/ml [16] 
Inhibits proteases (peptide bond breakers) 
that function in hemostatic and 
inflammatory reactions 
Table 3.1. General properties of some of the most abundant plasma proteins. 
3.3.2 Plasma Coagulation Assays 
The core of our studies will be the process of Plasma Coagulation.  
Plasma coagulation is the process by which blood generates a protective protein wall made 
of fibrin in order to prevent blood loss and haemorrhages. The development of this process 
depends on the action of several Coagulation Factors that are divided in two different pathways, 
depending on how the coagulation is activated: extrinsic pathway (studied through Prothrombin 
Time assays, PT), which is activated when a tissue has been injured; and intrinsic pathway 
(studied through Activated Partial Thromboplastin Time assays, APTT), activated when internal 
cells have been eroded or damaged. Both pathways eventually converge in a final Common 
pathway and are classically represented in the chain reaction known as the Coagulation 
Cascade, as seen in Figure 3.3 [17]. 
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As many other proteins, the factors inherent in this process have been found to interact with 
NPs and, due to protein conformational changes or deactivation, different consequences were 
observed. For instance, those NPs found to interact with Factor XII from the intrinsic pathway 
reported thrombosis induction (blood coagulation induction), whereas those NPs that interacted 
with Factor IV (Protein C, see Section 3.3.1, Table 3.1) were found to delay and obstruct 
thrombosis [18].  
In that context, our studies will evaluate and compare changes of development of both 
pathways in both rat and human plasma as described in Section 5.4.  
3.4 PREVIOUS PATHOPHYSIOLOGICAL STUDIES 
Pathophysiology, as a part of Pathology sciences, studies the mechanisms by which the 
organisms present altered physiological functions. As stated before, the presence of 
Nanoparticles in the organism results in an alteration of the proteins of the media when forming 
the protein corona, resulting in several consequences. Some of these studies reflect the 
importance of studying the effects of NPs in our organism: 
 NPs are able to change the protein structure once they are bound. For instance, it 
has been reported that, when interacting with silver nanoparticles, the percent of 
-helices from HAS (Human Serum Albumin: the most abundant protein in human 
plasma, essential for nutrient transportation among other functions) was reduced, 
whereas that of -sheets was increased [19]. Meaning that protein functionality 
Figure 3.3 Schematic representation of the Coagulation 
Cascade.  
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could dangerously mutate, or even disappear, as the nanoparticle is able to 
denaturalise it.  
 What is more, the protein corona may determine the path of the nanoparticles 
throughout the organism. It is able to modulate cellular uptake of the nanoparticles 
depending on the media they were pre-incubated in. For instance, after 2 hours of 
incubation of silver particles in a media containing albumin and IgG (common 
proteins found in Plasma), cellular uptake of the particles was reduced [19]. 
3.4.1 Previous Pathophysiological Studies Regarding ZnO NPs 
Regarding the NPs from our studies, ZnO NPs, significant findings have already been 
reported, which will help us understand our experimental results: 
 BSA (Bovine Serum Albumin, the biological behaviour of which is equivalent to 
Human’s Albumin) mutates its secondary structure when interacts with ZnO NPs; 
the percentage of -helices from the protein is reduced, whereas that of -sheets 
is increased [20]. Thus meaning, as previously stated, that its functionality could 
be dangerously altered or deactivated in contact with NPs. 
 ZnO causes a dose-dependent hemolytic activity (rupture of erythrocytes, red 
blood cells, that contain hemoglobin) activity. Although the exact mechanism 
remains unclear, data suggested that ZnO could enter into the cells and induce 
cell membrane rupture. <100nm NP reported the highest toxicity in these studies, 
inducing around 70% of hemolysis at concentrations of 0.2mg/ml (37ºC). 
In addition, it was observed how ZnO NPs could cause abnormal erythrocyte 
morphology when incubated for 3h (37ºC). Once again, <100nm NP caused the 
most significant morphological changes [21]. 
 ZnO caused significant dose-dependent plasma coagulation delays on human 
plasma when measuring both Intrinsic and Extrinsic pathways [21].  
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4. OBJECTIVES 
The present study is focused on evaluating toxicity caused by zinc oxide particles on both 
human and plasma.  
The aim of this study is four-fold: 
1. To characterize ZnO particles with different methodologies. 
2. To observe and compare the effect of zinc oxide particles on blood coagulation from both 
rat and human plasma. 
3. To qualitatively assess differences in affinity among the different plasma proteins to ZnO 
particles. 
4. To visually confirm the presence of protein corona through TEM. 
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5. EXPERIMENTAL SECTION 
5.1 REAGENTS 
5.1.1 General Reagents 
ZnO nanopowder <50 nm particle size (Sigma-Aldrich, >97%)  
ZnO nanopowder, <100 nm particle size (Sigma-Aldrich)  
ZnO puriss. p.a., ACS reagent (Sigma-Aldrich, ≥99.0%),  
PBS (Phosphate Buffered Saline): Potassium dihydrogen phosphate, extra pure (Scharlau), 
Sodium chloride, synthesis grade (Scharlau), di-Sodium hydrogen phosphate anhydrous 
(Panreac) at a concentration of 0.762 g/L, 7.056 g/L, 3.151 g/L, respectively, at pH=7.4.  
EDTA (Farmitalia Carlo Erba, RPE-for analysis-ACS reagent) 
Sodium Citrate p.a. (Sigma-Aldrich) 
5.1.2 Plasma Coagulation Assay Reagents 
Specific testing (Instrumentation Laboratory Co):  
RecombiPlasTin 2G (RTF and RTF Diluent): is a liposomal preparation that contains human 
RTF (recombinant human tissue factor) relipidated in a synthetic phospholipid blend and 
combined with calcium chloride, buffer and a preservative.  
SynthASil (ATTP Reagent – cephalin - and CaCl2): the ATTP is a liquid buffered reagent 
which contains synthetic phospholipid for optimal platelet-like activity and highly defined non-
setting colloidal silica for optimal activation of the contact phase of coagulation. 
5.1.3 Plasma Proteïn-ZnO Interaction Reagents 
Bovine Serum Albumin (Sigma-Aldrich, ≥96%)  
Coomassie brilliant blue G-250 (BioRad) 
D(+)-Sucrose (Carlo Erba Reagents, RPE-for analysis-ACS) 
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Formic Acid (Scharlau, 85%) 
Tris(hidroximetil)aminometà (Carlos Erga Reagents, RPE-for analysis) 
Hydrochloric acid (Scharlau, 37%, Reagent Grade) 
Sodium Dodecyl Sulfate (Sigma Aldrich, ≥98.5%) 
Persulfat amònic (Amersham Biosciences, 98%) 
Glycine (Scharlau, Reagent Grade, ACS) 
Bromophenol blue (Amersham Biosciences) 
b-mercaptotanol (Sigma Aldrich, ≥99%) 
Comassie Brillant Blue R-250 (Serva) 
Methanol (Scharlau, Reagent Grade) 
Glacial Acetic Acid (Scharlau, Reagent grade) 
Acrylamide PAGE (Amersham Biosciences, 40%) 
Methylenebisacrylamide (Amersham Biosciences, 2%w/v) 
N,N,N’,N’-Tetramethyl-ethylenediamine (Sigma-Aldrich, 99%) 
Phosphotungstic acid (2%, pH=6.4) 
5.2 INSTRUMENTS 
Centrifuge Megafuge 1.0 (Heraeus) and Centrifuge Biofuge Pico (Heraeus)  
Centrifuge Nahita Blue 2624/2 
Spectrophotometer Shimadzu UV-Vis 160  
Rotary shaker and temperature controlled cabin. 
Coagulometer Amleung KC 1A 
SDS-PAGE: Mini PROTEAN 3 system (BIORAD)  
Analytical Balance Sartorius CP1245 
Sonicator Fungilab 
Transmission Electron Microscopy (TEM) JEOL JEM LaB6-2100 
Dynamic Light Scattering (DLS) Malvern Zetasizer Nano ZS 
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5.3 CARACTERIZATION OF ZnO NANOPARTICLES 
Different properties of nanoparticles depend on parameters such as particle size, 
agglomeration (reflected on hydrodynamic diameter measures), particle charge, surface area or 
structural shape [8]. Therefore, in order to fully understand the behaviour of our nanoparticles 
throughout our study, it is essential characterize them.  
5.3.1 General Properties 
Properties 
ZnO nanopowder 
<50 nm 
ZnO nanopowder 
<100 nm 
ZnO  powder 
Size <50 nm <100 nm Micrometric 
Color White White White 
Solubility 1.6mg/L (Water, 29ºC) [22] 
Molar Mass 81.41 g/mol  
Crystal structure Hexagonal Wurtzite  [5] 
Surface Charge Negative (when suspended on PBS) [23] 
Abbreviation <50nm NP <100nm NP Micro P 
Table 5.1. General properties from ZnO NP used in our studies. Information extracted 
from provider (Sigma-Aldrich) if not specifically referenced. 
As our study is the continuation of many others, our particles are, in part, already 
characterized. Herein it was studied the shape and structure of our particles through X-ray 
diffraction, and hydrodynamic diameter through light-scattering. Characterization by TEM had 
been partly studied in previous work, although deeper studies have been realized in order to be 
able to detect the protein corona (See Section 5.6). 
5.3.2 X-Ray Characterization  
Each ZnO nanoparticle was dispersed in PBS media and studied through X ray in order to 
understand their crystalline structure and recognize possible differences among different sized 
particles. 
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5.3.3 Anticoagulant  
It is essential to control the stability of our particles in front of certain conditions inherent in 
our study. There will be used different blood anticoagulants (EDTA and Sodium citrate) through 
our analysis in order to prevent undesired plasma coagulation. Their effect is based on their 
ability to chelate the calcium present in our blood, which is essential to blood coagulation. 
Nevertheless, both anticoagulants are great chelants that could interact with our ZnO particles.  
Studies were performed in order to recognize the anticoagulant that provides greater 
stability to the ZnO nanoparticles. Blank solutions of each anticoagulant with each nanoparticle 
were elaborated as described in Table 5.2. NP's and anticoagulant concentrations in these 
blank solutions were equivalent to those used in Plasma coagulation assays. 
Entry Study PBS 
(L) 
NP’s 
Solution (L) 
Total Volume 
(L) 
Final NP’s 
Concentration 
(mg/ml) 
1 & 4 <50nm ZnO 900 90 990 0.9 
2 & 5 <100nm ZnO 900 90 990 0.9 
3 & 6 Micro P ZnO 900 90 990 0.9 
Table 5.2. Composition of the blank solutions studied. Each NP solution was prepared 
from 0.0050g of the respective NP in 500 L of PBS (10mg/ml), previously sonicated in order 
to prevent aggregation. Anticoagulant concentrations were 0.129M of sodium citrate for 
entries 1,2,3 and 2mg/ml of EDTA for entries 4,5,6. 
5.3.4 Hydrodynamic Diameter  
There is a tendency from particles to aggregate when suspended, so this method measures 
de sizes of the clustered particles rather than individual particles [24]. As protein corona is 
known to be formed when particles are suspended in plasma, different results are expected to 
be reported depending upon the media used. 
Each particle was suspended in PBS and citrated human plasma media as described in 
Table 5.3. Previous to measurement, particle control samples were sonicated. All samples were 
diluted 1:10 in MiliQ water in order to prevent further aggregation and potential measurement 
interferences. Measures contemplated ZnO’s Refractive Index of 2.00. 
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Entry Sample Plasma 
(L) 
PBS 
(L) 
Stock particle 
solution (L) 
Total Volume 
(L) 
NP’s Conc. 
(mg/ml) 
1 <50nm ZnO 
control 
- 900 90 990 0.9 
2 <100nm ZnO 
control 
- 900 90 900 0.9 
3 Micro ZnO 
control 
- 900 90 990 0.9 
4 Plasma control 900 90 - 990 - 
5 <50nm ZnO 900 - 90 990 0.9 
6 <100nm ZnO 900 - 90 990 0.9 
7 Micro ZnO 900 - 90 990 0.9 
Table 5.3. Composition of the solutions studied. Each stock particle solution was 
prepared from 0.0050g of the respective particle in 500 L of PBS resulting in concentrations 
of 10mg/ml, previously sonicated to prevent aggregation.  
5.4 PLASMA COAGULATION ASSAYS 
Plasma coagulation time was measured in order to study the effects of the presence of ZnO 
nanoparticles in both human and rat Plasma. Experimentation was based on pre-existing 
protocols [25]: Five different solutions were incubated at 37ºC, described at Table 5.4, for 30 
minutes. Three of them were composed by Plasma plus different sizes of NP’s (<50, <100 and 
micro) at a concentration of 0.9 mg/ml, the other two solutions were controls made from Plasma 
(Entry 1) and rat/human Plasma plus PBS (Entry 2).  
Once incubated, different coagulation assays were performed in order to study both 
extrinsic and intrinsic coagulation pathways. A coagulometer was used for that matter. 
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Entry Sample Plasma 
(L) 
PBS 
(L) 
NP’s Solution 
(L) 
Total 
Volume (L) 
Final NP’s 
Concentration 
(mg/ml) 
1 Plasma control 900 - - 900 0 
2 PBS control 900 90 - 990 0 
3 <50nm ZnO 900 - 90 990 0.9 
4 <100nm ZnO 900 - 90 990 0.9 
5 Micro ZnO 900 - 90 990 0.9 
Table 5.4. Composition of the solutions studied, both controls and NP’s samples. The 
same compositions were used for both human and rat Plasma. Each NP solution was 
prepared from 0.0050g of the respective NP in 500 L of PBS (10mg/ml), previously 
sonicated to prevent aggregation. 
This coagulometer includes a chronometer in order to measure the clot formation time while 
maintaining the temperature of the samples at 37ºC. It uses a special reaction cuvette with a 
steel ball inside in which the sample is added, inclined in a certain angle. The cuvette is always 
rotating around its longitudinal axis while the steel ball is held fixed in one position in the cuvette 
through the action of a small magnet. With the addition of the last reagent, Plasma clotting starts 
and the chronometer is manually activated. When the clots finally form, the ball gets blocked in 
one position thus starting to rotate with the cuvette. The change of position of the steel ball is 
registered by an electromagnetic sensor that automatically stops the chronometer. 
For extrinsic pathways studies, 100L of each solution reacted with 200L of calcic 
thromboplastin. Time measurement started once calcic thromboplastin was added. 
For intrinsic pathways studies, 100L of cephalin were added to 100L of each solution and 
left to react for 2 minutes. Then, 100L of CaCl2 were added and, instantly, time measurement 
started.  
5.4.1 Statistical Considerations  
Each assay was carried out individually, using three replicates for each sample. Human 
plasma assays were meant to be a mere test as they were already studied; only a couple of 
tests were performed. This was not the case for rat plasma assays, which were performed three 
times. 
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5.5 PLASMA PROTEIN-ZnO INTERACTION 
In order to study the different proteins involved in the protein coronas, and possible 
differences between supernatant and pellet, SDS-PAGE experiments were performed. 
5.5.1 Sample treatment 
Samples with NP were centrifuged (13.000 rpm, 5 min.) in order to separate the pellet from 
the supernatant and study them separately. We only studied the first supernatant of each 
sample. The pellets were washed 3 times with a solution of Sucrose 0.7M in PBS. Sucrose 
allows the pellet to precipitate in a more visual way, thus increasing the ease of separation from 
the supernatant [8].  
In these studies, bigger concentrations of protein are required (Read Section 5.5.2). It is 
expected that the concentration of protein from the hard corona is correlated to the 
concentration of the particles themselves. Therefore, herein is used a particle concentration 10 
times bigger than in plasma coagulation tests in order to gain sensibility, as described in Table 
5.5. Plasma and PBS controls prepared as in Entries 1 & 2 from Table 5.4 were always 
employed. 
Entry Study Plasma 
(L) 
NP’s Solution 
(L) 
Total Volume 
(L) 
Final NP’s 
Concentration 
(mg/ml) 
1 <50nm ZnO 900 90 990 9.0 
2 <100nm ZnO 900 90 990 9.0 
3 Micro ZnO 900 90 990 9.0 
Table 5.5. Composition of the NP’s samples studied. The same compositions were used for 
both human and rat Plasma. Each NP solution was made from 0.0500g of the respective NP in 
500 L of PBS (100 mg/ml), previously sonicated to prevent aggregation. 
5.5.2 SDS-PAGE 
SDS-PAGE stands for Sodium Dodecyl Sulfate Polyacrylamide Gel Electrophoresis. It is a 
technique widely used to separate different biological macromolecules, such as proteins, 
according to their different electrophoretic mobility. Proteins will be denaturalized (breaking of 
non-covalent bonds) through the addition of SDS (detergent). The same SDS charges the 
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proteins negatively as it bounds to them and it will make the proteins head to the anode of the 
cell. The electronic repulsion created by these negative charges flattens the shape of the 
proteins, thus eliminating any electrophoretic mobility differences caused by their shape. In 
addition, proteins will be denaturalized by heating them to 95ºC. 2-mercaptoethanol, a reducing 
agent of disulphide linkages, is also used to help denaturalizing the proteins in the sample. 
Finally, a tracking dye, bromophenol blue, is added to the samples. Unlike the proteins in the 
sample, this tracking dye can be seen (it is blue). Also, it has greater electrophoretic mobility 
than any of the compounds in the sample, so it helps keeping the pace of the experiment; when 
the tracking dye reaches the end of the gel, the electrophoresis is stopped. 
Note that proteomic quaternary structures are based on non-covalent bonds between 
several subunits, complexed as a whole. Therefore, due to the strong reductant media, multi-
subunit proteins are expected to be divided into every subunit that composes them. For 
instance, human fibrinogen (MW=340kDa) is broken into 3 main subunits: fibrinogen , 
MW=66kDa; fibrinogen , MW=52kDa ; fibrinogen , MW=46kDa [26]. 
Once protein samples are treated, they are disposed in different compartments in a 
Polyacrylamide gel, which is chemically inert. Our gels are 1mm thick. This gel is prepared 
maximum 24 hours before, as it can dry out and break.  
The gel is divided in two parts: the stacking gel and the running gel, as represented in 
Figure 5.3. Their purposes are clearly different. The proteins are injected in the cavities formed 
in the stacking gel. Once injected, with a subtle potential of 60 volts for 10 minutes, the stacking 
gel stacks all the proteins at the same point, a starting line, so they all start to migrate at the 
same time. This starting line is where the two different gels meet.  
 
 
 
 
 
The difference between these two gels is based on their composition. The Stacking gel has 
a lower percentage of acrylamide (5%), which means larger pores, and is buffered at pH=6.8. 
Meanwhile, the Running gel has a higher percentage of acrylamide (7.5%), narrower pores, and 
Figure 5.3. Representation of SDS-PAGE gels. 
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is buffered at pH=8.8, with different ionic content. The higher the pH, the higher negative charge 
bore by the proteins, thus making them more susceptible to the electrophoretic experiment. 
At a greater potential of 200 volts, the proteins enter the running gel and the migration 
starts. The running gel allows the separation of the different proteins based on their molecular 
weight. As it is known: the greater the protein, the slower its movement through the pores of the 
gel. The process is illustrated in Figure 5.4. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.4. Representation of SDS-PAGE experiments [27]. 
A special highly pure protein solution will be injected in one of the cavities. This solution 
contains few proteins of different mass that will be also separated by electrophoresis. Once 
revealed, this solution will provide a reference, a clear pattern, of size of the proteins in the 
samples. 
After electrophoresis, protein band stains are revealed when bathed in a solution of 
Comassie Brillant Blue R-250 (2.5g/L). Staining excess will be washed with a solution of 
methanol (7.5%) and Acetic acid (10%). 
Nevertheless, the amount of protein in each cavity must be controlled. All cavities should 
bear the same absolute amount of proteins (10-30 g), thus providing a clear separation of 
proteins so the different bands can be easily compared and studied. The Bradford method, used 
to analyse the concentrations of proteins in the samples, was previously performed for that 
matter (Section 5.5.3). 
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Herein, injected protein amounts were approximately of 18g from plasma controls and 
supernatants (SNs). Total injected protein amounts from particle pellets varied as they were not 
capable of retaining enough protein (Amounts injected are indicated when discussing each 
assay). Experience demonstrated that it was possible to study the stain bands as they were 
clear and comparable enough, even though the optimal amount of protein was not reached and 
homogeneous amount of protein among the cavities from the same gel was not possible to 
accomplish as experimental injection is complicated and part of the protein sample is likely to be 
lost. 
5.5.3 Bradford method 
The Bradford assay is a photometric method that, through different absorbance among the 
samples, allows us to determine the amount of protein in them. It is based on the use of a 
colorant, Coomassie brilliant blue G-250, that when bound to proteins changes its red colour to 
blue.  
From a stock solution of bovine albumin 1.5mg/ml, a standard analytical curve was 
designed as described in Table 5.6.  
St. Solution Stock sol. (l) PBS (l) Tot. Volume (l) Final Concentration 
(g/ml) 
1 50 1950 2000 37.5 
2 100 1900 2000 75 
3 200 1800 2000 150 
4 400 1600 2000 300 
5 666 1333 1999* 500 
6 1000 1000 2000 750 
Table 5.6. Composition of the standard solutions of albumin used to calibrate the study. 
(*) It supposes an error of 0.05% that can be neglected.  
Supernatant and control solutions, due to their expected high protein concentration- 
confirmed by few primary tests- were diluted 80 times before analysis. PBS was used as blank 
solution. 
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Before final absorbance measurement, each sample, control and standard solution was 
treated as follows: 50l of each sample were mixed with 50 l of formic acid, and stirred. Then, 
1.5 ml of colorant were added to the solution, and stirred. Colorant, BioRad’s Coomassie blue, 
was diluted 1:5 before use. Absorbance measurement was performed at 595nm. 
5.6 TEM STUDIES: PARTICLE CHARACTERIZATION AND PROTEIN CORONA 
Through TEM (Transmission Electronic Microscopy), ZnO particles were observed when 
diluted in mere H2O (MiliQ quality) and when incubated in human plasma (also eventually 
suspended in MiliQ water) in order to visually characterize our NPs and detect the protein 
corona. 
All samples were suspended in MiliQ water. Due to high particle aggregation, each control 
sample was diluted to contain 0.02g/ml of each kind of particle respectively (<50nm NP, 
<100nm NP and Micro P) in order to adequately observe the particles. In contrast, each protein 
incubated particles sample was prepared at a preventive concentration of 0.9g/ml (as Entries 
3, 4 and 5 from Table 5.4 on Section 5.4) due to loss of pellet after following washing; particles 
apparently increased their solubility in the aqueous media after protein incubation.  
All material was vigorously washed with MiliQ water in order to prevent sample 
contamination. Each sample was centrifuged and washed with MiliQ water at least 3 times. 
Measurements were made on a 5l drop of sample left to dry over a Holey Carbon-Copper grid. 
Control samples were sonicated before measurement. 
Proteins in our samples were revealed with phosphotungstic acid, which binds ionically to 
the positive charged groups, thus indicating whether protein was present or not around the 
particles. Phosphotungstic acid is electron dense and opaque to electron transmission, thus it is 
seen by TEM as dark staining. After drying the samples, a 5l drop of phosphotungstic acid was 
added over the sample grid and then removed after 30 seconds. One last 5l drop of water was 
added in order to eliminate potential excess of phosphotungstic acid, also removed after 30 
seconds. 
EDX (Energy-dispersive X-ray spectroscopy) analyses were performed to analyse the 
elemental composition of the sample, thus confirming the presence of plasma proteins, ZnO 
particles and the staining agent (tungsten, from the phosphotungstic acid). 
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TEM measurements were performed at the “Centres Científics i Tecnològics de la 
Universitat de Barcelona”. 
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6. ZnO PARTICLES CHARACTERIZATION: 
DISCUSSION 
6.1 X-RAY SPECTROSCOPY 
As seen in Figure 6.1, all three ZnO particles (Figure 6.1) share the same identical crystal 
system, thus meaning that no behavioural difference can be justified by structural differences 
among them. Moreover, they all hold the same ZnO’s crystalline structure pattern (d), hexagonal 
wurtzite (JCPDS pattern), thus meaning that no anomalies or significant defects in the structure 
of the particles are to be expected.  
 
 
a (a) (b) 
(c) (d) 
Figure 6.1. Representation of X-Ray diffraction spectroscopy results for ZnO particles: (a) <50nm, 
(b) <100nm, (c) micro). (d) corresponds to ZnO structural pattern, a hexagonal cell. 
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6.2 HYDRODYNAMIC DIAMETER 
Our findings show differential behaviour of the ZnO particles depending upon the media 
used, as seen in Table 6.1.  
Sample Z-ave Est. Desv. PDI 
<50nm ZnO control 2287 438.2 0.734 
<100nm ZnO control 1940.8 233.0 0.729 
Micro ZnO control 2448.2 1220.7 0.819 
Plasma control 106.5 19.8 0.789 
<50nm ZnO 166.1 4.6 0.188 
<100nm ZnO 245.0 3.8 0.147 
Micro ZnO 374.1 12.6 0.321 
Table 6.1. Hydrodynamic Diameters measured.  
Sizes measured from control samples are only qualitatively relevant due to the extremely 
high polydispersity index and standard deviation. It can be concluded that, when immersed in 
aqueous media, homogenic suspension is unstable and our particles quickly agglomerate and 
form random sized clusters. 
In contrast, after being incubated in Plasma, our particles significantly reduced the tendency 
to agglomerate and polydispersity diminished up to ideal values (0.0 - 0.3; polydispersity 
indexes below 0.1 are referred to be monodispersed systems) [28]. Reasonable nanoparticle 
size could be measured - note that these measures include the size of the particle itself as well 
as the volume acquired when forming the protein corona.  
Our findings already point out protein-NPs adsorption differences; Micro Ps still remain 
relatively polydispersed, much more than the other two NPs, thus meaning that their homogenic 
suspension has not been equally stabilized. Also, <50nm NP have relatively grown more from 
their initial sizing (from 30nm to 155.6nm, see Section 6.3) than <100 NPs (from 70nm to 
245.0nm) and Micro P (due to initial size dispersion, it cannot be reliably compared, though 
size variation seems quite subtle as previous to incubation there can be already found bigger 
particles in the sample). These phenomena agree with our findings on Section 7.2, where the 
greatest protein adsorption is reported on <50 nm NPs, then <100nm NPs and lastly in Micro P. 
In vitro safety assessment of nanomaterials: Protein corona studies on ZnO particles. 29 
 
6.3 TEM STUDIES: PARTICLE CHARACTERIZATION 
In figure 6.2 can be observed the structure of our particles when immersed in MiliQ water. 
As expected, NPs form great agglomerations when immersed in aqueous media. The same 
figure represents the clearest spots found in our samples.   
Figure 6.2 shows significant size dispersion among each kind of NPs, as well as completely 
amorphous shaping. Approximately, most of the <50nm NPs sized between 20 and 40nm 
(particle measures were made in situ through TEM), bigger particles seem to be particle 
clusters; <100nm NPs sized between 50-90nm, even though there can be clearly seen some 
particles bigger than 100nm; and Micro P mostly sized between 100 and 400nm, even though 
there could be found particles sizing less than 50nm.  
6.4 ANTICOAGULANT 
When stability studies were performed, the addition of EDTA to nanoparticle blank solutions 
(see Section 5.3.3, Table 5.2, Entries 1, 2 and 3) rapidly caused particle dissolution as the 
suspension lost its white color to the point of transparency; EDTA could not maintain our 
particles stable. 
Figure 6.2. TEM images from our particles <50nm NPs, <100nm NPs and Micro P 
immersed in MiliQ water.  
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EDTA has much higher affinity to Zn2+ than to Ca2+ [29], thus meaning that if EDTA is able to 
chelate our ZnO nanoparticles. As it was observed, chelated Ca2+ ions would be substituted by 
Zn2+, thus meaning that Ca2+ would be freed to the Plasma sample. The increase of Ca2+ ions in 
the media causes uncontrolled Plasma coagulation (Section 7.1.1.1, Table 7.1, Figure 7.1) 
In contrast, when sodium citrate was added to our nanoparticle blank solutions (see Section 
5.3.3, Table 5.2, Entries 4, 5 and 6) no observable change was observed.  
It is known that citrate shares approximately the same affinity to Zn2+ than to Ca2+ [29] so it 
is expected that the chelated Ca2+ is not substituted for Zn2+ when using citrate as easily as 
when using EDTA, thus meaning that our ZnO particles would stay more stable when using 
citrate than when using EDTA.  
For that reason, even though there could be potential Zn-Citrate complex formation - which 
due to problems with the methods of analysis (a nanometric filter was required), could not be 
quantified -, further studies were performed with sodium citrate as anticoagulant, instead of 
using EDTA. 
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7. PLASMA PROTEIN – ZnO INTERACTION: 
DISCUSSION 
7.1 PLASMA COAGULATION ASSAYS 
Nanoparticles are expected to interact with plasma proteins and consequently form the 
protein corona (see section 3.2). When bound to nanoparticles, proteins are known to lose their 
conformation and denaturalize (see section 3.4), thus altering metabolic processes. According 
to previous work [30], plasma coagulation is expected to be delayed,.  
As mentioned in Section 5.4, Plasma-protein assays were performed in rat and human 
plasma when incubated (37ºC for 30 minutes) with ZnO nanoparticles, firstly using EDTA and 
eventually using sodium citrate (see section 6.4). Extrinsic pathway was studied through PT 
assays and Intrinsic pathway was studied through APTT assays.  
7.1.1 Results from Rat Plasma Assays  
7.1.1.1 EDTA as Anticoagulant 
When using EDTA, the tests reported unexpected results described in Table 7.1 and 
represented on Figure 7.1. 
As can be seen in the Extrinsic coagulation graph, the smaller the particle, the shorter is the 
coagulation time. This is probably caused by differences of reactivity between the particles; the 
smaller the particle, the higher its surface area and greater its reactivity. EDTA could be 
interacting more intensively with <50nm NP than with Micro P. Therefore, more chelated Ca2+ 
ions could be replaced for Zn and freed to the media to trigger plasma coagulation.  
Intrinsic coagulation involves a much more complicated chain reaction. It is remarkable how 
<100nm NPs induced rapid coagulation while <50nm NPs never coagulated while incubating. 
Reasons that could cause these phenomena remain unknown. 
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  PT APTT 
Entry Sample Time (s) Est. Desv. (s) Time (s) Est. Desv. (s) 
1 Plasma Control 10.0 0.93 48.5 4.9 
2 PBS Control 10.1 1.40 56.5 5.07 
3 <50nm NP 7.1 2.04 54.9 5.08 
4 <100nm NP 9.2* 0.21* 0* 0* 
5 Micro P 10.7* 0.67* 45.6* 1.05* 
Table 7.1. Coagulation time measured by prothrombin and activated partial 
thromboplastin time on rat plasma incubated with different sized NP’s. EDTA was used as 
anticoagulant. Results based on 2 independent experiments of 3 replicates each. (*) Some of 
the replicates could not be properly studied as plasma coagulated while incubating. 
Figure 7.1. Extrinsic and Intrinsic coagulation results from Table 7.1. 
Independent nanoparticle stability tests (see Section 6.4) stated that EDTA chelated Zn2+ 
from our nanoparticles thus freeing previously chelated Ca2+ ions. The freeing of Ca2+ ions to 
the media explained the uncontrolled plasma coagulation reported, as Ca2+ ions are essential to 
blood coagulation (see Section 3.3.2).  
7.1.1.2 Sodium Citrate as Anticoagulant 
After independent tests of particle stability when using different anticoagulants (see section 
6.4), EDTA was changed into sodium citrate as anticoagulant. Results are described on Table 
7.2 and represented on Figure 7.2. 
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PT APTT 
Entry Sample Time (s) Est. Desv. (s) Time (s) Est. Desv. (s) 
1 Plasma Control 8.2 0.6 21.9 1.8 
2 PBS Control 8.2 0.8 21.3 1.7 
3 <50nm NP 14.9 2.8 -* -* 
4 <100nm NP 18.8 2.4 -* -* 
5 Micro P 17.6 2.4 221.6 (*) 72.3 (*) 
Table 7.2. Coagulation time measured by PT and APTT on rat plasma incubated with 
different sized NP’s. Results based on 3 independent experiments of 3 replicates each. Citrate 
was used as anticoagulant. (*) Not properly studied due to dispersion or absence of 
coagulation. 
 Figure 7.2. Extrinsic and Intrinsic coagulation results from Table 7.2. 
Our findings reflect a clear effect derived from ZnO particle incubation, plasma coagulation 
is significantly delayed in both pathways, especially on intrinsic coagulation. 
Intrinsic coagulation could not be properly studied as plasma, on most of the replicates, did 
not coagulate at all. The steel ball in the cuvette could freely move through the sample, thus 
meaning that there was no coagulation (see Section 5.4).  
However, the coagulometer did stop the chronometer, with unexplainable dispersion of 
clotting time measurements, on some the sample replicates that apparently were not 
coagulated. Closer inspection of the cuvettes, once the coagulometer stopped the chronometer, 
revealed that little weak clots were actually formed, although they were neither big nor strong 
enough to trap the steel ball. Occasionally, by chance, these clots could have slightly disturbed 
the movement of the steel ball. When this happened, the electromagnetic sensor of the 
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coagulometer momentarily lost the signal of the steel ball and stopped the chronometer with 
great dispersion of results.  
Chronometer was only stopped 3/9 times when measuring clotting time with <50nm NP 
samples while <100 nm NP samples did stop it in 5 of the 9 different replicates. Micro P was 
able to stop the chronometer 7/9 times, and even coagulated the plasma and blocked the ball’s 
movement in 4/9 times - These last few cases are reflected in Table 5, Entry 5, as information of 
no statistical relevance.  
The reported dispersion of results, and the impossibility to know whether some of the 
replicates did or did not coagulate - as the chronometer stopped although the steel ball could 
still move -, suggest that another methodology or instruments should be used in order, not only 
to quantify clotting time more precisely, but to measure clot strength as well.  
7.1.2 Results from Human Plasma Assays 
When using EDTA, human plasma coagulation reported similar anomalies to rat plasma; 
most of the samples coagulated before performing any assay, thus no significant results could 
be obtained. 
When using sodium citrate, human plasma behaved as expected from previous studies [21], 
thus meaning that, once the anticoagulant was changed, the conditions of our experiments 
equalled those of previous studies; it is assumed that our studies are a valid continuation of this 
previous work. 
Results obtained when using sodium citrate as anticoagulant are described in Table 7.3 and 
represented on Figure 7.3.  
As in rat plasma coagulation assays, plasma coagulation is significantly delayed. Results 
obtained agree with previous work [30]; the intrinsic coagulation is the most affected pathway 
and, in both pathways, 50<nm NPs cause the softest effect while 100<nm NPs and micro P 
cause higher, similar delays on clotting time. 
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  PT APTT 
Entr
y 
Sample Time (s) Est. Desv. (s) Time (s) Est. Desv. (s) 
1 Plasma Control 9.4 0.8 34.8 1.7 
2 PBS Control 9.6 0.8 35.2 1.6 
3 <50nm NP 18.9 0.3 373.1 44.1 
4 <100nm NP 23.6 0.8 521.0 53.8 
5 Micro P 21.9 0.9 522.3 57.3 
Table 7.3. Coagulation time measured by PT and APTT on human plasma incubated with 
different sized NP’s. Results based on 2 independent experiments of 3 replicates each. Citrate 
was used as anticoagulant.  
 Figure 7.3. Extrinsic and Intrinsic coagulation results from Table 7.3. 
It is stated that the stimulation of the intrinsic coagulation pathway and nanoparticle size 
could be  proportionally correlated [31] - meaning that the bigger the particle, the earlier plasma 
should coagulate – although this has only been found to apply in SiO2 particles. Our findings did 
not agree with this statement as they displayed reverse relation. 
Similar to rat plasma assays, clots formed when measuring APTT on some replicates was 
only enough to stop the chronometer from our coagulometer, but not to completely block the 
movement of the steel ball. This was reported to happen a couple of times when using <50nm 
NPs. As stated when discussing rat plasma results, these anomalies suggest the use of other 
methodologies or instruments in order to improve the reliability of our results from these assays. 
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7.1.3 Comparison between Rat and Human Coagulation 
Results for extrinsic coagulation reported similar results for both rat and human studies. In 
contrast, there could be observed great differences when measuring clotting time on the intrinsic 
coagulation cascade; rat’s intrinsic pathway was not just slowed as human’s, but completely 
obstructed. Moreover, their behaviour seems inversed. In human plasma, coagulation time 
increases in parallel with particle size whereas in the case of rat plasma coagulation is observed 
only when incubated with Micro P, but not in the presence of smaller sized nanoparticles that 
apparently impeded the coagulation.  
It should be noted that different behaviour between rat and human plasma is to be expected 
even in regular conditions [32]. One of the possible reasons for these changes is that rat plasma 
contains slightly lower concentration of fibrinogen and other important coagulating factors [33], 
thus meaning that higher relative quantity of coagulation proteins could be trapped, and 
deactivated, by the NP.  
Another reason that could explain these results is that rat and human plasma proteins, like 
fibrinogen, are not identical [34][35], thus potentially contributing to behavioural differences in 
front of ZnO NPs. 
In conclusion, equivalence between rat and human studies on ZnO nanotoxicity studies 
remains uncertain. Further studies should be adapted depending on the organism on which the 
study is performed. Anyway, differential behaviour between organisms could provide different 
perspectives to study the effects of ZnO nanoparticle absorption. 
7.2 PROTEIN QUANTIFICATION ASSAYS 
Although protein quantification assays were only meant to be orientative tests to optimize 
SDS-PAGE, results obtained from NP’s pellets were of significant value, as described in Table 
7.4. 
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Entry Solution 
[Total protein] Human plasma 
(mg/ml) 
[Total protein] Rat plasma 
(mg/ml) 
1 PBS Control 52777.6 44099.5 
2 <50nm NP – Pel* 681.5 670.0 
3 <100nm NP – Pel* 364.3 435.0 
4 Micro P – Pel* 177.9 205.8 
Table 7.4. Total protein concentration measured in pellets from different sized NPs 
incubated in human or rat plasma. Sodium citrate was used as anticoagulant. *Pel: particles’ 
pellet. 
It is stated that differential behaviour among NPs could be attributed on their size -and so of 
particle curvature and surface area [19]. This statement agrees with our data, as a clear 
correlation between total protein adsorbed by the NP’s and their size is observed; as the particle 
size diminishes, surface area and particle curvature increase and so does the total amount of 
protein adsorbed. This data will help to understand the results from the following SDS-PAGE 
and TEM assays.  
7.3 SDS-PAGE ASSAYS 
7.3.1 Human Gels Discussion 
Herein, only the most abundant proteins with characteristic and easy recognized stained 
bands, such as albumin and fibrinogen, could be reliably identified. For deeper understanding of 
the proteins adsorbed in the particles, gel digestion and further analytical assays should be 
performed. Moreover, these analyses could provide crucial information in order to understand 
the Protein-Particle interaction and predict potential physiological alterations. 
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Our findings show how certain proteins were adsorbed on the NPs with greater affinity than 
others. For instance, in Figure 7.4 (G, <50nm NPs pellet), the stained protein bands 
corresponding to fibrinogen  and  (due to reduction, fibrinogen breaks into 3 different 
subunits: , ,; see Section 5.5.2) are greater than the one of albumin, thus meaning that 
fibrinogen is present in greater concentration in the protein corona. Note that, in normal 
conditions, human plasma albumin is found in concentrations 20 times higher than fibrinogen 
(see section 3.3.1) as it can be observed in the control track (Figure 7.4, track A) which reveals 
a great stain band mainly constituted by albumin while the ones from fibrinogen  and remain 
regular sized. In conclusion, it can be assumed that fibrinogen has more affinity to ZnO NPs 
than albumin, especially to <50nm NPs. It should be noted that the albumin-fibrinogen relation 
varies with particle size, Track E (Micro Ps pellet) shows more albumin than fibrinogen.  
Figure 7.4. SDS-PAGE Human plasma. (A) Plasma Control; (B) Micro P, SN; 
(C) <100nm NP, SN; (D) <50nm NP, SN; (E) Micro P, Pellet; (F) <100nm NP, 
Pellet; (G) <50nm NP, Pellet; (P.P.) Protein pattern.  Approximated protein 
amount injected from pellets was 4g for A, B and C. 
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Fibrinogen presence on the protein corona could explain the delays on plasma coagulation 
reported on Section 7.1; if fibrinogen is trapped in the protein corona, it cannot perform its 
coagulation role as ZnO particles could be deactivating or denaturalizing it, as reported in 
previous studies to happen to numerous proteins (see Section 3.4). Even though, this would 
imply that the particles that adsorbed the most fibrinogen caused the greatest delays of plasma 
coagulation, which contradicts our findings on Section 7.1. Micro Ps seem to adsorb less 
fibrinogen, although their effects on plasma coagulation were more significant than <50nm NPs, 
that seemed to adsorb more fibrinogen. This suggests, as previously stated, the importance of 
further analysis and gel digestion, in order to accurately know each protein that was adsorbed 
on the particles that could alter physiological processes like plasma coagulation. 
Even though other proteins could not be identified, some band stains could be qualitatively 
compared as represented in Table 7.5. 
Approx. MW stain (kDa) <50 nm NP <100 nm NP Micro P control 
46 (Fibrinogen ) ++ ++ + +++ 
52 (Fibrinogen ) ++ ++ + +++ 
66 (Fibrinogen / Albumin) ++ ++ ++ +++ 
70 ++ + + ++ 
75 - + + ++ 
90 + - - + 
110 - - - + 
135 + + - + 
150 + - - + 
160 - - - ++ 
Table 7.5. Qualitative comparison of present protein stained bands in each particle track 
and plasma control from Figure 7.4 using human plasma. (+++) Great presence; (++) 
Significant presence; (+) Slightly present; (-) Apparently absent. 
Differences among NPs sizing are well observed. For instance, Track G from Figure 7.4 
reveals much greater fibrinogen  and  stains than Track F and E, thus meaning that 
fibrinogen has much more affinity to <50nm NPs than it does to the other particles. Moreover, 
most stains seem to pale as particle size grows, as global protein-particle affinity lowers with 
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bigger particles (see Section 7.2), although it is not the case for albumin/fibrinogen  stain that 
seems to gain significance. 
7.3.2 Rat Gels Discussion 
In parallel with human gels, only the most characteristic protein stain bands could be 
recognized without gel digestion and further analytical assays. This time, only albumin could be 
reliably identified within the pellet tracks whereas fibrinogen seemed to remain absent, thus 
meaning that possible differences in protein conformation (see Section 7.1.3) could provoke 
crucial adsorption differences. SDS- PAGE gels of rat plasma can be observed in Figure 7.5.  
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Figure 7.5. SDS-PAGE Rat plasma. (A) Micro P, Pellet; (B) <100nm NP, 
Pellet; (C) <50nm NP, Pellet; (D) Plasma Control; (E) Micro P, SN; (F) 
<100nm NP, SN; (G) <50nm NP, SN; (P.P.) Protein pattern. Approximated 
protein amount injected from pellets was 8g for C and B and 4g for A. 
Albumin 
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It should be noted that while in human gels it was mostly seen disappearance of stained 
bands, rat gels show the appearance of certain bands. <50nm NPs show a couple of significant 
stained bands of approximately 27 and 15 kDa that did only slightly appear in the control 
track, and all three particle tracks show the appearance of one band at approximately 85kDa 
that neither did appear in the control track. It is concluded that this bands are composed by 
proteins that are greatly adsorbed in our particles, thus significantly concentrating them in the 
pellet tracks while in regular rat plasma are found in diminutive amounts. 
Herein, Micro P’s track cannot be adequately compared to NPs’ tracks as it was not 
possible to concentrate them enough to inject the same amount of protein. However, there were 
found some differences between <50 and <100nm NPs. 15 and 27 kDa protein stained 
bands were only found in <50nm NPs and while the 72 kDa stain band is greater in <50nm 
NPs, 200kDa stain band is greater in <100nm NPs. 
As can be observed in rat plasma gels, in contrast with human plasma gels, albumin could 
be identified but fibrinogen was not. Rat fibrinogen breaks into different pieces compared to 
human fibrinogen; band stains from rat fibrinogen and weight the same (approximately 47 
kDa), and fibrinogenweights around 52 kDa [35]. Neither of these protein stain bands could 
be observed in our gels. 
The absence of fibrinogen trapped in the protein corona leaves us to suppose that delays on 
rat plasma coagulation could be rather caused by adsorption of other relevant coagulation 
factors instead of fibrinogen – in contrast with human plasma. Therefore, further analytical 
assays are essential to fully understand and discuss our findings, as previously stated. 
Once again, even though most proteins could not be identified, some band stains could be 
qualitatively compared as represented in Table 7.6. 
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Approx. MW stain (kDa) <50 nm NP <100 nm NP Micro P control 
12 + + + ++ 
15 ++ - - + 
27 ++ - - + 
47 (Fibrinogen ) NC NC - + 
52 (Fibrinogen ) NC NC - + 
66 (Albumin) ++ + + +++ 
72 ++ + + ++ 
85 + + + - 
90 + + + + 
110 - - - + 
145 - - - ++ 
200 + + + ++ 
Table 7.6. Qualitative comparison of present protein stained bands in each particle track 
and plasma control from Figure 7.5 using rat plasma. (+++) Great presence; (++) Significant 
presence; (+) Slightly present; (-) Apparently absent; (NC) Not Clear enough. 
7.3.3 General Comparison 
SDS-PAGE gels revealed different protein-NPs affinity profiles depending on the source of 
plasma or particle size, as can be observed in Figures 7.4 and 7.5.  
Differences among supernatants (Figure 7.4, tracks B, C, D; Figure 7.5, tracks D, F, G) can’t 
be identified as they lie upon the amount of proteins removed by the NPs from the original 
media, which is diminutive in comparison with the total amount of proteins that remain present in 
the sample. Possible experimental errors could suppose greater difference. 
Moreover, differences depending on the organism studied are well observed. As previously 
stated (see Section 7.1.3), plasma proteins from humans and rats are not identical, the 
conformations can differ thus provoking changes in their affinity to these NPs. For instance, 
most of human gel’s stained bands were found between 25 and 75kDa, while in rat gels stained 
bands were found all along the tracks. 
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7.4 TEM STUDIES: PROTEIN CORONA  
When immersed in plasma, TEM observations revealed protein accumulations around our 
particles, as can be seen in Figures 7.6, 7.7 and 7.8. Black spots correspond to particles and 
shadowy staining corresponds to plasma proteins. These findings should be compared to those 
on Section 6.3. 
 
Figure 7.6 Images taken from plasma incubated <50nm NPs. 
Figure 7.7 Images taken from plasma incubated <100nm NPs. 
Figure 7.8 Images taken from plasma incubated Micro Ps. 
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Organic substances are degraded by the electron beam while the observation takes place; 
as time went by, nanoparticles seemed to move as the surrounding proteic media that coated 
them was altered. Altogether, this degradation process proved protein presence. 
Protein presence was corroborated by elemental analysis (EDX) from the same TEM 
instrument. As can be seen in figure 7.9 as an example, shadowy staining around the particles 
from figures 7.6 to 7.8 reported presence of tungsten (see Section 5.6).  
Differences among particles were significant. <50nm NPs revealed large and dense stains 
of protein where our particles where immersed. Sometimes our particles could not be found 
within the stains. <100nm NPs displayed similar behaviour, although protein stains were lighter 
and clearer coating around the particles could be observed. On the other hand, Micro P 
revealed clear protein coating. No individual protein stains were found on Micro P samples. 
These phenomena agree with our findings and conclusions from Section 7.2. 
 
 
 
Figure 7.9 Elemental analyses from particles on the right picture from Figure 7.6. 
Presence of tungsten (W peaks) reveals protein presence that is corroborated, by C and 
S peaks. Zn peaks confirm the presence of our particles. Cu peaks correspond to the 
sample grid K peaks come from staining.  
 
C 
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8. CONCLUSIONS 
Following the objectives set on the beginning of our studies it can be concluded that: 
1. ZnO particles could be characterized. Our particles displayed total amorphous shaping 
and significant dispersion of particle size. When immersed in aqueous media, ZnO particles 
agglomerated rapidly, although that agglomeration was palliated when immersed in plasma. 
2. Blood coagulation profiles between rat and human plasma when incubated with ZnO 
particles proved to be significantly different when measuring the Intrinsic coagulation 
pathway. Rat’s blood intrinsic pathway was completely obstructed, in contrast with human’s 
intrinsic pathway – only delayed. Extrinsic pathway was found to be similarly affected. 
Nevertheless, another methodology should be used in order to perform more adequate 
studies. 
3. SDS-PAGE gels displayed clear differences in plasma protein-particle affinities 
depending upon species studied and particle size. Further deeper analytical assays should 
be performed in order to determine which proteins were adsorbed in each particle - and 
which ones did not -, therefore revealing common characteristics among the adsorbed 
proteins that could help understand and predict protein corona’s formation and behavior. 
4. Protein corona presence was visually confirmed on TEM observations and its quantitative 
presence – it was more present in <50nm NPs samples than in Micro P samples - was allied 
to our other findings. 
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10. ACRONYMS 
SDS Sodium Dodecyl Sulphate 
PAGE Polyacrylamide Gel Electrophoresis 
NP Nanoparticle 
SN Supernatant 
ATPP Activated Partial Thromboplastin time 
PT Prothrombin Time 
EDTA Ethylenediaminetetraacetic acid 
TEM Transmission electron microscopy 
PBS Phosphate-buffered saline 
MW Mass Weight 
EDX Energy-dispersive X-ray spectroscopy 
 
